These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 22144699

  • 21. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
    Lo MS, Newburger JW.
    Int J Rheum Dis; 2018 Jan; 21(1):64-69. PubMed ID: 29205910
    [Abstract] [Full Text] [Related]

  • 22. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM.
    J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
    [Abstract] [Full Text] [Related]

  • 23. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Apr; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 24. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 25. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 26. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 27; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 27. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 28. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.
    Kanai T, Takeshita S, Kawamura Y, Kinoshita K, Nakatani K, Iwashima S, Takizawa Y, Hirono K, Mori K, Yoshida Y, Nonoyama S.
    Heart Vessels; 2020 Oct 11; 35(10):1463-1472. PubMed ID: 32449049
    [Abstract] [Full Text] [Related]

  • 29. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 11; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

  • 30. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.
    Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T, Osaka Kawasaki Disease Study Group.
    Eur J Pediatr; 2009 Feb 11; 168(2):181-5. PubMed ID: 18446365
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.
    Kanamitsu K, Kakimoto H, Shimada A, Nakata Y, Ochi H, Watanabe H, Iwasaki Y, Tokorodani C, Kanazawa A, Maruyama H, Miyazawa M, Nishiuchi R, Kikkawa K.
    Pediatr Int; 2016 Feb 11; 58(2):146-51. PubMed ID: 26190225
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
    Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A.
    Pediatr Int; 2016 Mar 11; 58(3):180-184. PubMed ID: 26222760
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.